Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065468 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 626
- Enrollment target
NCT00065468: Completed Phase 3 study, sponsored by Pfizer.
NCT00065468 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 626 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00065468, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 626 participants
- Enrollment target
Study Summary
The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa \[IFN alfa\] subcutaneously \[SC\] three times per week \[TIW\], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.
Primary Outcome
Overall survival is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.
Interventions
- DRUG CCI-779
- DRUG Interferon Alfa
- DRUG Interferon Alfa and CCI-779
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 626 participants |
| Start Date | 2003-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
What the finished NCT00065468 record still lists
NCT00065468 is an interventional study that assigns participants to a tested intervention. The registered 626 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 3 interventions - of which CCI-779 is the first listed.
NCT00065468 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00065468 about?
NCT00065468 is a clinical study titled "Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma". The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Inter...
What is the current status of trial NCT00065468?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 626 participants. The study started on 2003-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00065468?
The interventions under investigation include: CCI-779 (DRUG), Interferon Alfa (DRUG), Interferon Alfa and CCI-779 (DRUG).
Who is sponsoring clinical trial NCT00065468?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00065468's enrollment target sits among peer trials
626 586th of 2000 higher than 1,415 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia